Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Course Instructor
Abby Massey
Capstone Semester
Fall 2020
Date of Graduation
12-17-2021
Abstract
As of October 2020, there are no commonly accepted or proven effective treatments for coronavirus disease 2019 (COVID-19). Hydroxychloroquine (HCQ) is an established anti-malarial drug with demonstrated action against SARS-CoV-2 (the virus that causes COVID-19) in-vitro and early observational studies and anecdotal evidence supported its use in treatment of COVID-19. In this review, three of largest and most statistically powerful studies to date (two cohort studies and one randomized controlled trial [RCT]) are synthesized for the purpose of determining whether HCQ is effective in reducing mortality in patients hospitalized with COVID-19. All three studies found no statistically significant difference in mortality between patients treated with HCQ and patients in a control group (receiving only standard care). Although evidence on the use of HCQ to treat COVID-19 has been conflicting and controversial, this review finds no evidence to support its continued use.
Document Type
Capstone
Recommended Citation
Suresh M, Abraham J. The Effect of Hydroxychloroquine on Mortality in Hospitalized COVID-19 Patients
